Drugs / vytorin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VYTORIN | — | 2004-07-23 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00092651 | Sep 2002 → Jun 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01666067 Comparator | Nov 2011 → Oct 2012 | hyperlipidemia | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01660945 Comparator | Jul 2011 → Jul 2012 | hyperlipidemia | Gachon University Gil Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vytorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01660945 ↗ |
| Known as | MK0653A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00092651 ↗ |